This company has been acquired
OMIC Stock Overview
A life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Singular Genomics Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.01 |
| 52 Week High | US$23.41 |
| 52 Week Low | US$5.34 |
| Beta | 1.84 |
| 1 Month Change | 0.81% |
| 3 Month Change | -6.58% |
| 1 Year Change | 21.27% |
| 3 Year Change | -91.92% |
| 5 Year Change | n/a |
| Change since IPO | -97.41% |
Recent News & Updates
Shareholder Returns
| OMIC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.3% | -3.3% | -0.3% |
| 1Y | 21.3% | -30.4% | 8.1% |
Return vs Industry: OMIC exceeded the US Life Sciences industry which returned -14.6% over the past year.
Return vs Market: OMIC matched the US Market which returned 20.8% over the past year.
Price Volatility
| OMIC volatility | |
|---|---|
| OMIC Average Weekly Movement | 3.7% |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: OMIC has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OMIC's weekly volatility has decreased from 22% to 4% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 255 | Drew Spaventa | www.singulargenomics.com |
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.
Singular Genomics Systems, Inc. Fundamentals Summary
| OMIC fundamental statistics | |
|---|---|
| Market cap | US$50.70m |
| Earnings (TTM) | -US$86.32m |
| Revenue (TTM) | US$2.67m |
19.0x
P/S Ratio-0.6x
P/E RatioIs OMIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMIC income statement (TTM) | |
|---|---|
| Revenue | US$2.67m |
| Cost of Revenue | US$4.02m |
| Gross Profit | -US$1.35m |
| Other Expenses | US$84.97m |
| Earnings | -US$86.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -34.07 |
| Gross Margin | -50.77% |
| Net Profit Margin | -3,236.67% |
| Debt/Equity Ratio | 8.4% |
How did OMIC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 08:58 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Singular Genomics Systems, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ryskin | BofA Global Research |
| null null | Equisights |
| Matthew Sykes | Goldman Sachs |